β-blockers in the management of hypertension: Focus on nebivolol

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 4, 2008, Pages 471-479

  Wojciechowski, David ^a   Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

blockers; Hypertension; Nebivolol; Nitric oxide

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BYSTOLIC; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUOXETINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; NIFEDIPINE; PINDOLOL; PLACEBO; PROPRANOLOL; RAMIPRIL; RANITIDINE; SPIRONOLACTONE; UNCLASSIFIED DRUG; WARFARIN; ANTIOXIDANT; BENZOPYRAN DERIVATIVE; ETHANOLAMINE DERIVATIVE; NITRIC OXIDE;

AIRWAY OBSTRUCTION; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIAL DYSFUNCTION; FATIGUE; HEART RATE; HUMAN; HYPERTENSION; HYPESTHESIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; METABOLIC PARAMETERS; MONOTHERAPY; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; SEXUAL DYSFUNCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASODILATATION; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; METABOLISM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIOXIDANTS; BENZOPYRANS; BLOOD PRESSURE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; NITRIC OXIDE;

EID: 43049179911     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.4.471     Document Type: Article

References (62)

1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States, 1999 to 2000: a rising tide. Hypertension 44, 398-404 (2004).
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J. Am. Med. Assoc. 290, 199-206 (2003).
3. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch. Intern. Med. 161, 1183-1192 (2001).
4. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the USA: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161, 1207-1216 (2001).
5. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am. J. Hypertens. 7(7Pt 2), S7-S12 (1994).
6. Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J. 25, 1341-1362 (2004).
7. Ubel PA, Jepson C, Asch DA. Misperceptions about β-blockers and diuretics: a national survey of primary care physicians. J. Gen. Intern. Med. 18, 977-983 (2003).
8. Ko DT, Hebert PR, Coffey CS et al. β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J. Am. Med. Assoc. 288, 351-357 (2002).
9. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am. J. Hypertens. 11, 1258-1265 (1998).
10. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 364, 1684-1689 (2004).
11. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366, 1545-1553 (2005).
12. Weber M. The role of the new β-blockers in treating cardiovascular disease. Am. J. Hypertens. 18, 169S-176S (2005).
13. Gielen W, Cleophas TJ, Agrawal R. Nebivolol. A review of its clinical and pharmacological characteristics. Int. J. Clin. Pharmacol. Ther. 44, 344-357 (2006).
14. Prichard BNC. Pharmacologic aspects of intrinsic sympathomimetic activity in β-blocking drugs. Am. J. Cardiol. 59, 13F-17F (1987).
15. McDevitt DG. Pharmacologic aspects of cardioselectivity in a β-blocking drug. Am. J. Cardiol. 59, 10F-12F (1987).
16. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 101, 558-569 (2000).
17. Bristow M. Characterization of β1-adrenergic receptor selectivity of nebivolol and various β-blockers in human myocardium. Am. J. Hypertens. 18(Pt 2), 51A-52A (2005).
18. Moen MD, Wagstaff AJ. Nebivolol. A review of its use in the management of hypertension and chronic heart failure. Drugs 66, 1389-1409 (2006).
19. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation β-blocker. Blood Pressure 13 (S1), 3-17 (2004).
20. Bowman AJ, Chen CPL-H, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmac. 38, 199-204 (1994).
21. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-argiriine/ NO-dependent mechanism. J. Pharmacol. Exp. Ther. 274, 1067-1071 (1995).
22. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 104, 511-514 (2001).
23. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey (1988-1991). Hypertension 25, 305-313 (1995).
24. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J. Am. Coll. Cardiol. 40, 754-760 (2002).
25. McEniery CM, Schmitt M, Qasem A et al. Nebivolol increases arterial distensibility in vivo. Hypertension 44, 305-310 (2004).
26. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112, 3795-3801 (2005).
27. Pasini AF, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 23, 589-596 (2005).
28. Falciani M, Rinaldi B, D'Agostino B et al. Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 38, 922-929 (2001).
29. Brehm BR, Wolf SC, Bertsch D et al. Effects of ncbivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res. 49, 430-439 (2001).
30. Pessina AC. Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol. 38(Suppl. 3), 33-35 (2001).
31. Poirier L, Cléroux J, Nadeau A et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. 19, 1429-1435 (2001).
32. Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective β1-adrenoceptor antagonist, nebivolol. Cardiovasc. Drug Rev. 22, 155-168 (2004).
33. Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 24, 591-596 (2006).
34. Uhlir O, Dvorak I, Gregor P et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J. Card. Fail. 3, 271-276 (1997).
35. Dal Negro RW, Tognella S, Micheletto C. Pharmacokinetics of the effect of nebivolol 5mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension: a randomized, placebo-controlled study. Clin. Drug Invest. 22, 197-204 (2002).
36. Dal Negro RW, Tognella S, Pomari C. Once-daily nebivolol 5mg doses does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension: a placebo-controlled crossover study. Clin. Drug Invest. 22, 361-367 (2002).
37. 2-receptor antagonists cimetidine and ranitidine. Br. J. Clin. Pharmacol. 43, 201-204 (1997).
38. Shaw AA, Ziemniak J, Liu S et al. Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers [abstract]. Clin. Pharmacol. Ther. 77, 77 (2005).
39. Cheymol G, Woestenborghs R, Snoeck E et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur. J. Clin. Pharmacol. 51, 493-498 (1997).
40. Gu Z, Robinson RA, Cai L et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes [abstract]. AAPS PharmSci 5, T3362 (2003).
41. Janssens WJ, Snoeck E. Pharmacology and pharmacokinetics of nebivolol. Symposium on endothelium in hypertension. New Therapeutic Trends. 1, 10-13 (1997).
42. Lawrence TE, Liu S, Fisher JW et al. No interaction between nebivolol and digoxin in healthy volunteers [abstract]. Clin. Pharmacol. Ther. 77, 76 (2005).
43. Lawrence TE, Chien C, Tu HC et al. Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffectcd by nebivolol in healthy volunteers [abstract]. Clin. Pharmacol. Ther. 77, 39 (2005).
44. Lawrence TE, Chien C, Tu HC et al. No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status [abstract]. Clin. Pharmacol. Ther. 77, 82 (2005).
45. Morton TL, Tu HC, Liu S et al. Lack of pharmacokinetic interaction between nebivolol and spironolactone [abstract]. Clin. Pharmacol. Ther. 77(2), 46 (2005).
46. Morton TL, Liu S, Phillips JL et al. Pharmacokinetics of nebivolol and ramipril are not affected by co-administration [abstract]. Clin. Pharmacol. Ther. 77, 77 (2005).
47. Morton TL, Liu S, Phillips JL et al. No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects [abstract]. Clin. Pharmacol. Ther. 77, 79 (2005).
48. Shaw AA, Liu S, Zachwieja LF et al. Effect of chronic administration of fluoxetine on the pharmacokinetics of nebivolol [abstract]. Clin. Pharmacol. Ther. 77, 38 (2005).
49. Van Bortel LMAB, Breed JGS, Joosten J, Kragten JA, Lustermans FATh, Mooij JMV. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its annhypertensive efficacy and impact on quality of life. J. Cardiovasc. Pharmacol. 21, 856-862 (1993).
50. Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J. Hum. Hypertens. 11, 139-144 (1997).
51. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild to moderate hypertension. J. Clin. Hypertens. 9, 667-676 (2007).
52. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J. Clin. Hypertens. 9, 866-875 (2007).
53. Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. 12, 135-140 (1998).
54. Czuriga I, Riecansky I, Bodnar J et al. Comparison of the new cardioselective β-blocker nebivolol with bisoprolol in hypertension: the nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc. Drugs Ther. 17, 257-263 (2003).
55. Uhlir O, Fejfusa M, Havranek K et al. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest. 3 (S1), 107-110 (1991).
56. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RHG. Nitric oxide, erectile dysfunction and β-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharm. Phys. 34, 327-331 (2007).
57. Van Nueten L, Lacourciere Y, Vyssoulis G et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized comparative trial. Am. J. Ther. 5, 237-243 (1998).
58. Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina C. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 11, 182-188 (2002).
59. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JIS. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. 11, 813-819 (1997).
60. Rosei EA, Rizzoni D, Comini S, Boari G. Evaluation of die efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press. 12 (S1), 30-35 (2003).
61. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am. J. Hypertens. 18, 1060-1066 (2005).
62. Lacourciere Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am. J. Hypertens. 7, 137-145 (1994).